| 1 |
33855585 | Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial. | 2022 Feb |
2 |
| 2 |
34687791 | Induction of IL-6Rα by ATF3 enhances IL-6 mediated sorafenib and regorafenib resistance in hepatocellular carcinoma. | 2022 Jan 1 |
3 |
| 3 |
32918399 | Sorafenib reduces steatosis-induced fibrogenesis in a human 3D co-culture model of non-alcoholic fatty liver disease. | 2021 Feb |
1 |
| 4 |
33432366 | IL‑6 plays a crucial role in epithelial‑mesenchymal transition and pro‑metastasis induced by sorafenib in liver cancer. | 2021 Mar |
4 |
| 5 |
32103983 | LncRNA DANCR Promotes Sorafenib Resistance via Activation of IL-6/STAT3 Signaling in Hepatocellular Carcinoma Cells. | 2020 |
2 |
| 6 |
33061451 | IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells. | 2020 |
10 |
| 7 |
33273830 | Erratum: IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells [Corrigendum]. | 2020 |
1 |
| 8 |
31387809 | Decreased IL-6 induces sensitivity of hepatocellular carcinoma cells to sorafenib. | 2019 Oct |
5 |
| 9 |
31771617 | DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation. | 2019 Nov 26 |
2 |
| 10 |
30154433 | ID1-induced p16/IL6 axis activation contributes to the resistant of hepatocellular carcinoma cells to sorafenib. | 2018 Aug 28 |
9 |
| 11 |
30369518 | Interleukin-6 induces drug resistance in renal cell carcinoma. | 2018 Dec 8 |
1 |
| 12 |
27841868 | Long noncoding RNA-SRLR elicits intrinsic sorafenib resistance via evoking IL-6/STAT3 axis in renal cell carcinoma. | 2017 Apr 6 |
3 |
| 13 |
28903416 | Overriding TKI resistance of renal cell carcinoma by combination therapy with IL-6 receptor blockade. | 2017 Aug 15 |
1 |
| 14 |
29100435 | Effect of TALEN-mediated IL-6 knockout on cell proliferation, apoptosis, invasion and anti-cancer therapy in hepatocellular carcinoma (HCC-LM3) cells. | 2017 Sep 29 |
4 |
| 15 |
29137334 | The coffee diterpene kahweol enhances sensitivity to sorafenib in human renal carcinoma Caki cells through down-regulation of Mcl-1 and c-FLIP expression. | 2017 Oct 10 |
1 |
| 16 |
27131739 | Effect of adipocyte-secreted factors on EpCAM+/CD133+ hepatic stem cell population. | 2016 Jun 3 |
1 |
| 17 |
26244291 | Regulation of ADAM10 and ADAM17 by Sorafenib Inhibits Epithelial-to-Mesenchymal Transition in Epstein-Barr Virus-Infected Retinal Pigment Epithelial Cells. | 2015 Aug |
1 |
| 18 |
24833103 | Epithelial to mesenchymal transition is associated with shorter disease-free survival in hepatocellular carcinoma. | 2014 Nov |
1 |
| 19 |
22406995 | Sorafenib inhibits endogenous and IL-6/S1P induced JAK2-STAT3 signaling in human neuroblastoma, associated with growth suppression and apoptosis. | 2012 May |
2 |
| 20 |
21331764 | Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells. | 2011 Jun |
1 |
| 21 |
21342228 | Sorafenib-associated hand-foot syndrome in Japanese patients. | 2011 Mar |
1 |